Intellia Therapeutics (NTLA) Misses Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Cowen on Intellia Therapeutics (NTLA): 'We continue to view NTLA as a leader in the gene editing space'
August 4, 2022 11:06 AM EDTCowen analyst Joseph Thome reiterated an Outperform rating and {REMOVEPT} price target on Intellia Therapeutics (NASDAQ: NTLA)
The analyst comments "NTLA remains on track to present initial data from NTLA-2001 in ATTR-CM and NTLA-2002 in HAE in H2:22. The... More
RBC Capital on Intellia Therapeutics (NTLA) as Shares Like Over 10%: 'Stock Reaction Overdone'
August 4, 2022 10:17 AM EDTRBC Capital analyst Luca Issi reiterated an Outperform rating and $150.00 price target on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "NTLA announced today a new case of possibly drug-related liver enzyme elevation at 1 mg/kg and is backing off the dose going forward from... More
